ArticleInternational journal of chronic obstructive pulmonary disease2021
Inhaled Corticosteroid Therapy in Bronchiectasis is Associated with All-Cause Mortality: A Prospective Cohort Study.
Article in International journal of chronic obstructive pulmonary disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis.BMC pulmonary medicine · 2026Pooled it
- Inhaled Corticosteroid Use and Risk ofJournal of clinical medicine · 2025Article
- Cardiovascular disease as a prognostic factor for mortality in non-cystic fibrosis bronchiectasis: data from the Taiwan Bronchiectasis Research Collaboration.ERJ open research · 2025Article
- Inhaled Corticosteroids and the Risk of Lung Cancer in Patients with Bronchiectasis.Journal of clinical medicine · 2025Article
- Inflammatory Phenotypes of Bronchiectasis.Journal of personalized medicine · 2025Review
- Bronchodilators and inhaled corticosteroids use in major global bronchiectasis registries.Journal of thoracic disease · 2025Article
- Retrospective cross-sectional study on bronchiectasis in adult Aboriginal Australians: disease characteristics and comparison with ethnically diverse global bronchiectasis registry cohorts.BMJ open respiratory research · 2025Article
- Exacerbations of bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Differential response to roflumilast in patients with chronic obstructive pulmonary disease: real-world evidence.Journal of thoracic disease · 2024Article
- Factors influencing survival and mortality among adult Aboriginal Australians with bronchiectasis-A 10-year retrospective study.Frontiers in medicine · 2024Article
- Exacerbation Prevention and Management of Bronchiectasis.Tuberculosis and respiratory diseases · 2023Article
- Blood eosinophil percentage as a predictor of response to inhaled corticosteroid in bronchiectasis.The clinical respiratory journal · 2023Article
- Exploring the appropriateness of prescribing practice of inhaled pharmacotherapy among Aboriginal Australians in the Top End Northern Territory of Australia: a retrospective cohort study.BMJ open respiratory research · 2023Article
- Article
- The hidden epidemic of post-tuberculosis bronchiectasis.African journal of thoracic and critical care medicine · 2023Article
- Review
- Inhaled corticosteroid dose is associated withBMJ open respiratory research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Prescribing inhaled corticosteroids (ICS) for bronchiectasis (BE) in the absence of obstructive lung disease is controversial. Studies investigating ICS therapy and impact on morbidity and mortality in BE are sparse. Methods: This study comprises all patients with BE managed at respiratory outpatient clinics at two university hospitals in the Capital Region of Denmark 2014-2015. Baseline data were obtained from patient medical records, and patients were followed until April 2020. Results: Out of 264 patients, 122 (46%) were prescribed ICS with no demographic differences between users/non-users of ICS. Among patients prescribed ICS, 21% did not have a concomitant diagnosis of asthma or COPD. Patients prescribed ICS had lower lung function (median FEV Conclusion: In this cohort, close to one out of five patients with BE were prescribed ICS despite having no concomitant diagnosis of asthma or COPD. Overall, ICS treatment was associated with higher morbidity and mortality, though causation is difficult to establish.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.